Imv Inc (IMVIF)
IMV Inc is a clinical-stage biotechnology company focused on immuno-oncology. Its research platform is built around DPX, a technology designed to stimulate immune responses for use in cancer therapies. The company’s most advanced candidate is maveropepimut-S, a DPX-based immunotherapy being studied in Phase II trials for diffuse large B-cell lymphoma, ovarian cancer, bladder cancer, liver cancer, and MSI-H solid tumors, and in Phase I testing for breast cancer. IMV also is developing DPX-SurMAGE for bladder cancer, along with DPX-COVID-19 and DPX-RSV for infectious diseases. The company was established in 2000, changed its name from Immunovaccine Inc. in 2018, and is headquartered in Dartmouth, Canada.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-IMVI.F
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
0.014 K
|
—
|
—
|
—
|
—
|
—
|
—
|